维奈克拉联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病:一项1b期研究
这项1b期剂量递增试验在49例复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者中评估维奈克拉联合利妥昔单抗的安全性、药代动力学和疗效。维奈克拉联合利妥昔单抗的2期推荐剂量为400 mg,未确定最大耐受剂量。49例中42例(86%)获得缓解,25例(51%)获得完全缓解,28例(57%)达到骨髓微小残留病阴性,安全性可接受。
要点
- 维奈克拉联合利妥昔单抗的2期推荐剂量为400 mg,最大耐受剂量未确定。
- 49例中42例(86%)缓解,25例(51%)完全缓解,28例(57%)骨髓微小残留病阴性。
- 3-4级不良事件见于37例(76%),最常见为中性粒细胞减少26例(53%)。
核心结论
- 相当比例患者获得总缓解,包括49例中25例(51%)完全缓解和28例(57%)骨髓微小残留病阴性,安全性可接受。
- 观察到的缓解深度和持久性为复发或难治性慢性淋巴细胞白血病患者提供了有吸引力的潜在治疗选择,并可能使部分患者停药后维持缓解,该策略值得在随机研究中进一步探讨。
研究设计与样本
- 1b期剂量递增试验,纳入根据2008年修改版国际慢性淋巴细胞白血病工作组指南定义的复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤成人患者。
- 主要结局为评估安全性、确定最大耐受剂量及确立维奈克拉联合利妥昔单抗的2期推荐剂量;次要结局为评估药代动力学和疗效,包括总缓解、缓解持续时间和至肿瘤进展时间。
- 微小残留病为方案规定的探索性目标;未进行终点中心审查。
- 维奈克拉每日给药,逐步递增至目标剂量(200-600 mg),随后开始每月利妥昔单抗(第1个月375 mg/m2,第2-6个月500 mg/m2)。
- 2012年8月6日至2014年5月28日共入组49例患者。
主要发现
- 常见1-2级毒性包括上呼吸道感染(49例中28例[57%])、腹泻(27例[55%])和恶心(25例[51%])。
- 3-4级不良事件见于49例中37例(76%),最常见为中性粒细胞减少(26例[53%])、血小板减少(8例[16%])、贫血(7例[14%])、发热性中性粒细胞减少(6例[12%])和白细胞减少(6例[12%])。
- 常见严重不良事件为发热(6例[12%])、发热性中性粒细胞减少(5例[10%])、下呼吸道感染和肺炎(各3例[6%])。
- 2例以维奈克拉50 mg起始的患者发生临床肿瘤溶解综合征(导致1例死亡);加强肿瘤溶解综合征预防措施并以维奈克拉20 mg起始后,未再发生临床肿瘤溶解综合征。
- 49例中42例(86%)获得缓解,包括25例(51%)完全缓解;无进展生存和持续缓解的2年估计值分别为82%(95%CI 66-91)和89%(95%CI 72-96)。
关键数值与推荐
- 维奈克拉联合利妥昔单抗的2期推荐剂量为400 mg;最大耐受剂量未确定。
- 维奈克拉每日给药,逐步递增至目标剂量(200-600 mg),随后每月利妥昔单抗(第1个月375 mg/m2,第2-6个月500 mg/m2)。
- 达到完全缓解(包括骨髓恢复不完全的完全缓解)或骨髓微小残留病阴性的患者允许按方案停药。
临床怎么用
- 作者认为,维奈克拉联合利妥昔单抗观察到的缓解深度和持久性为复发或难治性慢性淋巴细胞白血病患者提供了有吸引力的潜在治疗选择。
- 作者认为,该联合方案可能使部分患者停药后维持缓解,该策略值得在随机研究中进一步探讨。
局限性
- 未进行终点中心审查。
- 患者仍在接受治疗,随访正在进行中。
- 该策略值得在随机研究中进一步探讨。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combination with rituximab. METHODS: Adult patients with relapsed or refractory chronic lymphocytic leukaemia (according to the 2008 Modified International Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase 1b, dose-escalation trial. The primary outcomes were to assess the safety profile, to determine the maximum tolerated dose, and to establish the recommended phase 2 dose of venetoclax when given in combination with rituximab. Secondary outcomes were to assess the pharmacokinetic profile and analyse efficacy, including overall response, duration of response, and time to tumour progression. Minimal residual disease was a protocol-specified exploratory objective. Central review of the endpoints was not done. Venetoclax was dosed daily using a stepwise escalation to target doses (200-600 mg) and then monthly rituximab commenced (375 mg/m2 in month 1 and 500 mg/m2 in months 2-6). Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for adverse events version 4.0. Protocol-guided drug cessation was allowed for patients who achieved complete response (including complete response with incomplete marrow recovery) or negative bone marrow minimal residual disease. Analyses were done per protocol for all patients who commenced drug and included all patients who received at least one dose of venetoclax. Data were pooled across dose cohorts. Patients are still receiving therapy and follow-up is ongoing. The trial is registered at ClinicalTrials.gov, number NCT01682616. FINDINGS: Between Aug 6, 2012, and May 28, 2014, we enrolled 49 patients. Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 patients), diarrhoea (27 [55%]), and nausea (25 [51%]). Grade 3-4 adverse events occurred in 37 (76%) of 49 patients; most common were neutropenia (26 [53%]), thrombocytopenia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12%]). The most common serious adverse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each three [6%]). Clinical tumour lysis syndrome occurred in two patients (resulting in one death) who initiated venetoclax at 50 mg. After enhancing tumour lysis syndrome prophylaxis measures and commencing venetoclax at 20 mg, clinical tumour lysis syndrome did not occur. The maximum tolerated dose was not identified; the recommended phase 2 dose of venetoclax in combination with rituximab was 400 mg. Overall, 42 (86%) of 49 patients achieved a response, including a complete response in 25 (51%) of 49 patients. 2 year estimates for progression-free survival and ongoing response were 82% (95% CI 66-91) and 89% (95% CI 72-96), respectively. Negative marrow minimal residual disease was attained in 20 (80%) of 25 complete responders and 28 (57%) of 49 patients overall. 13 responders ceased all therapy; among these all 11 minimal residual disease-negative responders remain progression-free off therapy. Two with minimal residual disease-positive complete response progressed after 24 months off therapy and re-attained response after re-initiation of venetoclax. INTERPRETATION: A substantial proportion of patients achieved an overall response with the combination of venetoclax and rituximab including 25 (51%) of 49 patients who achieved a complete response and 28 (57%) of 49 patients who achieved negative marrow minimal residual disease with acceptable safety. The depth and durability of responses observed with the combination offers an attractive potential treatment option for patients with relapsed or refractory chronic lymphocytic leukaemia and could allow some patients to maintain response after discontinuing therapy, a strategy that warrants further investigation in randomised studies. FUNDING: AbbVie Inc and Genentech Inc.
引用
- Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017. PMID: 28089635. doi:10.1016/S1470-2045(17)30012-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。